Product Description
a new 99mTc-labeled myocardial perfusion imaging agent for the detection of myocardial perfusion abnormalities, with those of 201Tl and coronary angiography. (Sourced from: https://www.ahajournals.org/doi/10.1161/01.CIR.91.2.313)
Mechanisms of Action: Radioactive Agent
Novel Mechanism: No
Modality: Diagnostic Agent
Route of Administration: Injection
FDA Designation: None *
Approval Status: Approved
Approved Countries: Australia | Austria | Belgium | Bulgaria | Canada | Cyprus | Czech | Finland | France | Germany | Greece | Hong Kong | Hungary | Indonesia | Ireland | Israel | Italy | Latvia | Lithuania | Malaysia | Malta | Netherlands | Norway | Peru | Portugal | Romania | Russia | Singapore | Slovakia | Slovenia | Sweden | Switzerland | Taiwan | Turkey | United Kingdom | United States
Approved Indications: None
Known Adverse Events: None
Company: None
Company Location:
Company CEO:
Additonal Commercial Interests: None
Clinical Description
Countries in Clinic:
Active Clinical Trial Count:
Highest Development Phases
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
---|